Prenumeration
On December 17th, STENOCARE announced that the company has received approval for a new product in Denmark, CBD100, which has a high concentration of CBD active ingredients (100 mg/ml). This makes STENOCARE the only supplier to offer a CBD100 oil product in Denmark.
In summary, we view positively on the news of the approved CBD100 oil product, as it further solidifies STENOCARE’s position as a leading supplier in Denmark and provides an additional option for doctors and patients in Denmark, as this is the only medical cannabis oil product with this concentration of CBD, which is seen as a competitive advantage.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.